scPharmaceuticals, which is commercializing an injectable version of an intravenous drug for heart failure, announced terms for its IPO on Tuesday.
The Burlington, MA-based company plans to raise $96 million by offering 6.4 million shares at a price range of $14 to $16. At the midpoint of the proposed range, scPharmaceuticals would command a fully diluted market value of $276 million.
scPharmaceuticals was founded in 2013 and plans to list on the Nasdaq under the symbol SCPH. Jefferies, Leerink Partners and BMO Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of November 13, 2017.
